January 11, 2023

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan.

Five suspected copper cable thieves appear in court

POTCHEFSTROOM – A total of five men, accused of copper cable theft, has on Tuesday, 10 January 2023, appeared briefly before the Christiana Magistrate’s Court on a charge of possession of suspected stolen property.The accused court’s appearance stems f…

A male was killed by a train at a level crossing

HEIDEDAL – A pedestrian was hit and killed by a train on a level crossing near Heidedal in Bloemfontein.On Wednesday, 11 January 2023 at about 07:30, Heidedal police received a call about a train accident near East-end Industrial Park. On arrival, memb…

Recent Posts